The efficacy is not different in people with and without obesity except for AstraZeneca which is not known, according to a new position statement from The Obesity Society TOS , the leading scientific membership organization advancing the science-based understanding of the causes, consequences, prevention and treatment of obesity.
Trials have demonstrated high efficacy in individuals with and without obesity against COVIDassociated hospitalization and death. Therefore, TOS encourages individuals with obesity to undergo vaccination with any of the available vaccines authorized for emergency use by the U.
Food and Drug Administration as soon as they are able. This was not the case for obesity. Because the prevalence of obesity among trial participants was high, and because obesity is highly associated with hospital admission and death in COVID, the trial results were able to show that, contrary to concerns of reduced vaccine efficacy in people with obesity, that the vaccines were just as efficacious among persons with obesity compared with persons without obesity," said Alexandra M.
Hajduk, Ph. Hajduk is one of the co-authors of the position statement. In addition, obesity is associated with conditions that are independent risk factors and predictors of mortality from COVID, including diabetes, cardiovascular, cerebrovascular and pulmonary diseases.
On Dec. Authors of the position statement wrote the document in response to published literature, as well as inquiries made to the Society by patients, providers, Society members, policymakers and others regarding the efficacy of vaccines in persons with obesity against SARS-CoV I hope this position statement not only will encourage those with and without obesity to get vaccinated, but to continue the conversations on the existing weight bias in our current health policies and poor coverage and reimbursement of effective treatments for obesity," said first author, W.
Further stratification by age revealed vaccine efficacy of younger adults age with obesity Post hoc analysis reported a vaccine efficacy of Vaccine efficacy 14 days after dose one was In an interim sub-group analysis of participants with one or more comorbidities, the vaccine efficacy was The specific vaccine efficacy and safety data in persons with obesity is not yet published.
The following recommendations are currently endorsed by TOS regarding vaccine efficacy in persons with obesity:. TOS plans to monitor emerging data on vaccine efficacy and will issue an updated evidence-based position statement at a future time. These vaccines work in individuals with and without obesity. We want to end this pandemic. Let's make it happen by getting vaccinated," said Catherine Kotz, Ph.
Kotz is a co-author of the position statement. As individuals with obesity have a greater risk of severe COVID, in a sense they have even more to gain by getting vaccinated, preventing heart-breaking outcomes. By getting vaccinated, we are protecting ourselves and each other; let's get vaccinated!
Poland says that he has urged pharmaceutical companies to stratify their data by BMI, but he worries that the word is not getting out. Even if antibody responses seem robust, that could be misleading, cautions Melinda Beck, who studies the relationship between nutrition and immune responses at the University of North Carolina. And analyses so far have focused on Western definitions of obesity. These are based on BMI, a crude measure that fails to distinguish between fat that accumulates under the skin, and fat that accumulates around organs, called visceral fat, which is more closely associated with diseases such as diabetes and high blood pressure.
In people of European descent, a BMI of 30 kilograms per square metre or above is considered obese. China is the only country to set a lower threshold — a BMI of 28 kg m —2 — for obesity, but even then, Popkin says, some Chinese researchers will report their data using Western definitions of BMI to improve their chances of publishing.
Ultimately, the world will probably need to wait for data from clinical studies to show the way, says Drucker. But the waiting could be nerve-wracking. Vandanmagsar, B. Nature Med. PubMed Article Google Scholar. Hagan, T. Cell , — Frasca, D. Article Google Scholar. Download references. News 13 JAN News 12 JAN News 11 JAN News Feature 12 JAN World View 11 JAN University of Maryland School of Medicine. University of Guelph. Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.
Advanced search. Skip to main content Thank you for visiting nature. With So that's a concern," said Laurens. It's not entirely clear to experts why vaccines don't seem to work as well in obese patients, but there are a number of theories. One thought is that the typical one-inch needle routinely used for immunizations is not long enough for use in obese adults. This is because the fat layer under the skin may be thick enough that the needle can't reach the underlying shoulder muscle, where the vaccine liquid needs to be deposited to have its best shot at working.
Another theory is that obese adults, because of their increased body mass, may actually need a bigger dose -- or even a booster dose -- of the vaccine to properly ready their immune system to fight off the virus. According to Dr. But could the coronavirus vaccine be different and provide equal protection for both the obese and the non-obese? I think you could say it's possible. The new technology is different," said Laurens, referring to the novel mRNA technology being used in the coronavirus vaccine trial he's currently spearheading.
For now, perhaps the only way to know for sure whether the vaccine will work in the obese is to include them in large phase 3 trials -- the last step before authorization from the Food and Drug Administration.
0コメント